Published in J Exp Med on July 01, 1994
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol (1999) 4.04
The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev (2001) 3.65
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
CD44 cell adhesion molecules. Mol Pathol (1999) 2.89
Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest (1996) 2.86
Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med (1997) 2.11
Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol (2000) 1.93
Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion. J Clin Invest (1998) 1.83
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma (2011) 1.68
Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking. J Exp Med (2000) 1.65
Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J Exp Med (1995) 1.62
CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol (1999) 1.60
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem (2002) 1.60
Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol (2008) 1.52
Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res (2008) 1.47
AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol (1997) 1.46
Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma (2011) 1.46
Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm (2008) 1.45
The normal structure and function of CD44 and its role in neoplasia. Mol Pathol (1998) 1.44
Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol (1995) 1.43
Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem (2001) 1.36
Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J Exp Med (1995) 1.35
Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol Biol Cell (1999) 1.33
Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J Cell Biol (1996) 1.31
CD44 in inflammation and metastasis. Glycoconj J (1997) 1.16
CD44 and the adhesion of neoplastic cells. Mol Pathol (1997) 1.12
Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost (2006) 1.09
Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am J Pathol (2000) 1.09
Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia (2004) 1.08
Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Am J Pathol (1996) 1.05
Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J Exp Med (1996) 1.03
Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. J Control Release (2010) 1.00
Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am J Pathol (2007) 1.00
Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl Med (2015) 0.99
Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol (2000) 0.98
Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells. Am J Pathol (2003) 0.97
Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. J Invest Dermatol (2009) 0.96
Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol (2012) 0.94
Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor. J Biol Chem (2010) 0.92
A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells. Nucleic Acids Res (2014) 0.91
Mycobacteria exploit host hyaluronan for efficient extracellular replication. PLoS Pathog (2009) 0.90
Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity. J Cell Biol (1995) 0.90
Recent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies. J Cell Mol Med (2009) 0.88
CD44 and HCELL: preventing hematogenous metastasis at step 1. FEBS Lett (2011) 0.88
Proteome analysis of multidrug-resistant, breast cancer-derived microparticles. J Extracell Vesicles (2014) 0.87
CD44-stimulated dendrite formation ('spreading') in activated B cells. Immunology (1997) 0.83
Expression and localization of membrane-type-1 matrix metalloproteinase, CD 44, and laminin-5gamma2 chain during colorectal carcinoma tumor progression. Virchows Arch (2004) 0.83
Does DG42 synthesize hyaluronan or chitin?: A controversy about oligosaccharides in vertebrate development. Proc Natl Acad Sci U S A (1996) 0.83
Hyaluronan fragments promote inflammation by down-regulating the anti-inflammatory A2a receptor. Am J Respir Cell Mol Biol (2011) 0.83
Hyaluronan production in human rheumatoid fibroblastic synovial lining cells is increased by interleukin 1 beta but inhibited by transforming growth factor beta 1. Ann Rheum Dis (1998) 0.82
Differential expression of CD44(S) and variant isoforms v3, v10 in three-dimensional cultures of mouse melanoma cell lines. Clin Exp Metastasis (2002) 0.82
Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variant exon products. Am J Pathol (1999) 0.82
Hyaluronan binding motifs of USP17 and SDS3 exhibit anti-tumor activity. PLoS One (2012) 0.81
Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol (1999) 0.81
A simple method for the synthesis of hyaluronic acid coated magnetic nanoparticles for highly efficient cell labelling and in vivo imaging. RSC Adv (2011) 0.81
CD44s-targeted treatment with monoclonal antibody blocks intracerebral invasion and growth of 9L gliosarcoma. Clin Exp Metastasis (1999) 0.81
CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells. Immunology (1995) 0.81
Ca(2+)/calmodulin-dependent protein kinase mediates the phosphorylation of CD44 required for cell migration on hyaluronan. Biochem J (2001) 0.80
Restoration of CD44H expression in colon carcinomas reduces tumorigenicity. Ann Surg (1995) 0.80
Growth as a solid tumor or reduced glucose concentrations in culture reversibly induce CD44-mediated hyaluronan recognition by Chinese hamster ovary cells. J Clin Invest (1997) 0.80
Receptor for Hyaluronic Acid-Mediated Motility is Associated with Poor Survival in Pancreatic Ductal Adenocarcinoma. J Cancer (2015) 0.79
Spatio-temporal patterns of pancreatic cancer cells expressing CD44 isoforms on supported membranes displaying hyaluronic acid oligomers arrays. PLoS One (2012) 0.77
Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. Cancer Prev Res (Phila) (2016) 0.76
Antiproliferative Effects of 1α-OH-vitD3 in Malignant Melanoma: Potential Therapeutic implications. Sci Rep (2017) 0.75
Expression patterns of CD44 adhesion molecule in testicular germ cell tumors and normal testes. Am J Pathol (1998) 0.75
CD44 is the principal cell surface receptor for hyaluronate. Cell (1990) 11.01
Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc Natl Acad Sci U S A (1987) 10.38
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (1991) 7.29
Hyaluronan. FASEB J (1992) 6.67
Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A (1992) 4.90
Proteoglycans as modulators of growth factor activities. Cell (1991) 4.45
A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell (1989) 4.39
Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med (1990) 3.78
A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell (1989) 3.57
The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J (1991) 3.20
CD44--a molecule involved in leukocyte adherence and T-cell activation. Immunol Today (1989) 2.96
Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem (1988) 2.72
Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol (1991) 2.57
Dual role of the CD44 molecule in T cell adhesion and activation. J Immunol (1989) 2.53
Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol (1992) 2.52
CD44 contributes to T cell activation. J Immunol (1989) 2.44
CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res (1991) 2.36
The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol (1990) 2.32
Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody. J Exp Med (1992) 2.30
CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol (1992) 2.28
Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med (1991) 2.23
LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science (1990) 2.09
A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol (1993) 2.06
Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem (1992) 2.03
Hyaluronate and invasiveness of the rabbit V2 carcinoma. Proc Natl Acad Sci U S A (1979) 1.96
The hyaluronate receptor is associated with actin filaments. J Cell Biol (1987) 1.85
Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-alpha-dependent mechanism in murine macrophages. J Clin Invest (1993) 1.82
Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. J Immunol (1990) 1.78
Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol (1993) 1.77
The role and regulation of tumour-associated hyaluronan. Ciba Found Symp (1989) 1.68
The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell (1993) 1.58
Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia (1990) 1.48
The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol (1992) 1.44
Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. J Exp Med (1992) 1.36
Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol (1993) 1.34
Molecular isoforms of murine CD44 and evidence that the membrane proximal domain is not critical for hyaluronate recognition. J Cell Biol (1992) 1.27
A cell surface integral membrane glycoprotein of 85,000 mol wt (gp85) associated with triton X-100-insoluble cell skeleton. J Cell Biol (1984) 1.26
Lymphoma protein kinase C is associated with the transmembrane glycoprotein, GP85, and may function in GP85-ankyrin binding. J Biol Chem (1989) 1.16
Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev (1991) 1.14
Similar epithelial-stromal interactions in the regulation of hyaluronate production during limb morphogenesis and tumor invasion. Cancer Lett (1990) 1.07
Migration of human melanoma cells on hyaluronate is related to CD44 expression. J Invest Dermatol (1993) 1.04
Confirmation by peptide sequence and co-expression on various cell types of the identity of CD44 and P85 glycoprotein. Mol Immunol (1990) 0.96
Generation and characterization of the murine monoclonal antibody M-KID 2 to VLA-3 integrin. Hybridoma (1991) 0.89
Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A (1987) 12.15
CD44 is the principal cell surface receptor for hyaluronate. Cell (1990) 11.01
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (1996) 6.61
A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A (1992) 4.77
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science (1990) 3.74
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 3.73
Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol (1996) 3.56
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med (1997) 3.31
Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science (1993) 3.30
The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J (1991) 3.20
gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med (1994) 2.87
Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int (2007) 2.75
Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity (1996) 2.74
In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med (1993) 2.72
The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol (1993) 2.53
Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med (1992) 2.42
Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci U S A (1996) 2.40
Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med (1996) 2.39
CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A (1996) 2.38
CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol (1995) 2.38
Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol (1992) 2.36
CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol (1992) 2.28
The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, CD75, on B cells. Cell (1991) 2.24
Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med (1984) 2.24
Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med (1991) 2.23
Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A (1993) 2.17
Expression of functional CD40 by vascular endothelial cells. J Exp Med (1995) 2.16
Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res (2001) 2.12
Leu-8/TQ1 is the human equivalent of the Mel-14 lymph node homing receptor. Nature (1989) 2.12
Characterization and cloning of a novel glycoprotein expressed by stromal cells in T-dependent areas of peripheral lymphoid tissues. J Exp Med (1992) 2.11
Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med (1997) 2.11
Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J Pathol (2007) 2.03
The primary structure of the human leukocyte antigen CD37, a species homologue of the rat MRC OX-44 antigen. J Exp Med (1989) 1.99
Ability of bacteria associated with chronic inflammatory disease to stimulate E-selectin expression and promote neutrophil adhesion. Infect Immun (1995) 1.95
CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci U S A (1994) 1.94
CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today (1992) 1.93
Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood (1998) 1.89
Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol (1995) 1.84
A transmembrane-anchored chimeric focal adhesion kinase is constitutively activated and phosphorylated at tyrosine residues identical to pp125FAK. J Biol Chem (1994) 1.83
Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+T lymphocytes. Proc Natl Acad Sci U S A (1991) 1.81
Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol (1995) 1.78
Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol (1993) 1.77
Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood (1997) 1.77
Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP). J Histochem Cytochem (1994) 1.72
Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science (1991) 1.67
Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood (1993) 1.67
CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation (1996) 1.63
Isolation of cDNAs for two distinct human Fc receptors by ligand affinity cloning. EMBO J (1988) 1.60
CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int (1997) 1.57
Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. J Biol Chem (1993) 1.49
Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res (1995) 1.48
Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J Exp Med (1995) 1.47
CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J Biol Chem (1993) 1.46
Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol (1998) 1.43
Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol (1995) 1.43
Late administration of monoclonal antibody to leukocyte function-antigen 1 abrogates incipient murine cerebral malaria. Eur J Immunol (1991) 1.42
Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest (1994) 1.41
Diminished expression of CD40 ligand by activated neonatal T cells. J Clin Invest (1995) 1.39
Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. J Immunol (1994) 1.39
Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. J Exp Med (1992) 1.36
T-cell activation molecule 4-1BB binds to extracellular matrix proteins. Proc Natl Acad Sci U S A (1992) 1.36
Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer (1998) 1.35
An essential role for gp39, the ligand for CD40, in thymic selection. J Exp Med (1995) 1.35
B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J Exp Med (1993) 1.35
Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A (1997) 1.35
GMP-140 (P-selectin/CD62) binds to chronically stimulated but not resting CD4+ T lymphocytes and regulates their production of proinflammatory cytokines. Eur J Immunol (1992) 1.33
Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells. J Biol Chem (1995) 1.33
Interleukin-6 signal transducer gp130 mediates oncostatin M signaling. J Biol Chem (1992) 1.31
Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J Cell Biol (1996) 1.31
CD44 as a receptor for colonization of the pharynx by group A Streptococcus. J Clin Invest (2000) 1.30
Filamin binds to the cytoplasmic domain of the beta1-integrin. Identification of amino acids responsible for this interaction. J Biol Chem (1998) 1.28
Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med (1996) 1.27
CD44 binds to the Shigella IpaB protein and participates in bacterial invasion of epithelial cells. Cell Microbiol (2000) 1.24
Cytokine-induced beta-galactoside alpha-2,6-sialyltransferase in human endothelial cells mediates alpha 2,6-sialylation of adhesion molecules and CD22 ligands. J Biol Chem (1994) 1.24
Fas and tumor necrosis factor receptor-mediated cell death: similarities and distinctions. J Exp Med (1994) 1.23
In the absence of a CD40 signal, B cells are tolerogenic. Immunity (1995) 1.23
CD2/LFA-3 ligation induces phospholipase-C gamma 1 tyrosine phosphorylation and regulates CD3 signaling. J Immunol (1992) 1.22
CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest (2000) 1.22
Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. Eur J Immunol (1997) 1.22
Extending the B7 (CD80) gene family. Protein Sci (1994) 1.22
CD80 costimulation is essential for the induction of airway eosinophilia. J Exp Med (1997) 1.21
Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem (1996) 1.21
The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function. J Biol Chem (1996) 1.20
Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci U S A (1992) 1.18